Phylogica Ltd (PYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Phylogica Ltd (PYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH82400D
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Phylogica Ltd (Phylogica) is a biotechnology company that develops intracellular biological therapeutics. The company utilizes proprietary phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates. Its products include libraries and peptides. Phylogica's Phylomer libraries are in variety of phage display and yeast-two-hybrid formats and in mammalian expression vectors for phenotypic screening through which peptides are derived. The company's oncology candidate's pipeline programs include Myc, STAT5 and YB1. The company discovers and patents peptide therapeutics which exhibit competitive therapeutic, manufacturing, and commercial advantages over proteins, monoclonal antibodies and most current therapeutic peptides. Phylogica is headquartered in Mount Pleasant, Australia.

Phylogica Ltd (PYC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Phylogica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Phylogica Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Phylogica Enters Into Co-Marketing Agreement With Bio-Link For Anti-Inflammatory Phylomers 11

Licensing Agreements 12

Phylogica Enters into Licensing Agreement with PhoreMost 12

Phylogica Extends Licensing Agreement with Genentech 13

Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 14

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 15

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 16

Equity Offering 17

Phylogica to Raise Funds through Private Placement of Shares 17

Phylogica Raises USD3.8 Million in Private Placement of Shares 18

Phylogica Raises USD6.7 Million in Rights Offering of Shares 19

Phylogica Completes Rights Offering Of Shares For USD 3.3 Million 20

Phylogica Ltd-Key Competitors 21

Phylogica Ltd-Key Employees 22

Phylogica Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Feb 28, 2018: Phylogica: Financial Reoprt For Half Year Ended 31 December 2017 24

Aug 31, 2017: Phylogica: Preliminary Final Report For Year ended 30 June 2017 27

Feb 27, 2017: Phylogica Reports H1 Fiscal 2017 28

Corporate Communications 29

Apr 11, 2018: Phylogica: Changes To Board and Management 29

Jan 03, 2018: Phylogica: Appointment of Non-Executive Director 30

Nov 21, 2017: Professor Paul Watt joins Phylogica Scientific Advisory Board 31

Jul 24, 2017: Phylogica: Appointment of Company Secretary and change of Registered Office 32

Jun 19, 2017: Phylogica Announces Appointments of CEO and Chief Science Officer, and Secures USD 5 Million in New Funding 33

Apr 18, 2017: Phylogica Appoints Renowned Pharmaceutical Executives as Non-Executive Directors 35

Mar 31, 2017: Phylogica: Resignation of Secretary 37

Legal and Regulatory 38

Apr 03, 2017: Phylogica Announces the Launch of its New Website 38

Government and Public Interest 39

Mar 02, 2018: Cre enzyme delivery provides further validation and strategic value 39

Product News 40

Sep 05, 2017: Phylogica: New delivery vehicles show improved performance inside cells 40

Other Significant Developments 41

Jul 31, 2018: Phylogica: Operational Update-June Quarter 41

Jul 30, 2018: Phylogica: Achievement of major milestone-successful in vivo Cre delivery 43

Jul 27, 2018: Phylogica: Successful in vivo results-peptide vaccine T-cell expansion 44

Jan 31, 2018: Phylogica: Operational update and conference call-December quarter 45

Oct 25, 2017: Phylogica: Operational update and conference call-September quarter 46

Jul 11, 2017: Phylogica: Operational Update 47

Apr 04, 2017: Phylogica Announces an Operational Update 49

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Phylogica Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Phylogica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Phylogica Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Phylogica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Phylogica Enters Into Co-Marketing Agreement With Bio-Link For Anti-Inflammatory Phylomers 11

Phylogica Enters into Licensing Agreement with PhoreMost 12

Phylogica Extends Licensing Agreement with Genentech 13

Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 14

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 15

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 16

Phylogica to Raise Funds through Private Placement of Shares 17

Phylogica Raises USD3.8 Million in Private Placement of Shares 18

Phylogica Raises USD6.7 Million in Rights Offering of Shares 19

Phylogica Completes Rights Offering Of Shares For USD 3.3 Million 20

Phylogica Ltd, Key Competitors 21

Phylogica Ltd, Key Employees 22

Phylogica Ltd, Other Locations 23

Phylogica Ltd, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Phylogica Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com